Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Byung Kwon Ahn 3 Articles
Clinical Characteristics of Multiple Primary Colorectal Cancers
Joo Won Yoon, Seung Hyun Lee, Byung Kwon Ahn, Sung Uhn Baek
Cancer Res Treat. 2008;40(2):71-74.   Published online June 30, 2008
DOI: https://doi.org/10.4143/crt.2008.40.2.71
AbstractAbstract PDFPubReaderePub
Purpose

Although multiple primary colorectal cancer has been recognized as a significant clinical entity, its clinical and pathological features and its prognosis are still controversial. The purpose of this study was to clarify clinical and pathological features of multiple primary colorectal cancer.

Materials and Methods

Among 1669 patients who underwent surgery for primary colorectal cancer from January 1997 to June 2005, 26 patients (1.6%) with multiple primary colorectal cancer were identified. We reviewed clinical characteristics including diagnostic interval, lesions, operating methods, and TNM stage, and we defined the index lesion as the most advanced lesion among the synchronous lesions. For the purposes of the study, the colon and rectum were classified into three segments. The right-side colon included the appendix, cecum, ascending colon, hepatic flexure, and transverse colon, and the left-side colon included the splenic flexure, descending colon, and sigmoid colon.

Results

Of the 26 patients with multiple primary colorectal cancers, nineteen patients were male and seven patients were female, with a mean age of 61.5 years. Nineteen patients had synchronous colorectal cancers and seven patients had metachronous colorectal cancers. In the metachronous cases, the mean diagnostic interval was 36.8 months. The site of the first lesion in metachronous colorectal cancers was the right colon in five cases (71.4%) and the left colon in two cases (28.6%), and the site of the second lesion was the rectum in six cases (55.5%), the right colon in three cases (33.3%), and the left colon in one case. The TNM stage of the second lesions in the metachronous colorectal cancers was stage II in four cases (57.1%), stage III in one case (14.3%), and stage IV in one case (14.3%). For the synchronous colorectal cancers, the operation methods were single-segment resection combined with endoscopic mucosal resection in five cases (26.3%), single-segment resection alone in six cases, two-segment resection in six cases, and total colectomy in two cases.

Conclusion

In metachronous colorectal cancers, the secondary lesions were later-stage cancer. Therefore, careful postoperative follow-up is necessary for patients who have undergone surgery for colorectal cancers. Further study of therapeutic modalities is important for synchronous colorectal cancers.

Citations

Citations to this article as recorded by  
  • A nomogram for predicting the overall survival in rectal cancer patients after total neoadjuvant therapy
    Z. Liu, M. He, X. Wang
    Techniques in Coloproctology.2024;[Epub]     CrossRef
  • Developing prognostic nomograms to predict overall survival and cancer-specific survival in synchronous multiple primary colorectal cancer based on the SEER database
    Xiangyu Zhang, Yanpeng Hu, Kai Deng, Wanbo Ren, Jie Zhang, Cuicui Liu, Baoqing Ma
    Journal of Cancer Research and Clinical Oncology.2023; 149(15): 14057.     CrossRef
  • A Pathomimetic Colorectal Tumor‐on‐a‐Chip for In Vitro Reconstitution of the Primary Colorectal Cancer
    Zhangcai Liu, Ziming Yu, Jianpei Dong, Deyu Yang, Juanhua Li, Zhen He, Jianhua Zhou, Lu Huang
    Advanced Materials Technologies.2023;[Epub]     CrossRef
  • The incidence of second primary cancer in male and female patients with initial colorectal cancer: a SEER population-based study
    Yanyan Chen, Chao Han, Yadi Huang, Chao Liu, Siqi Sheng, Linlin Ji, Jialong Zhu, Gongbo Fu, Xiaobei Mao, Mengxi Huang, Zengjie Lei, Xiaoyuan Chu
    European Journal of Cancer Prevention.2022; 31(5): 430.     CrossRef
  • Tissue Displacement Versus Two Primary Colorectal Carcinomas? A Case Report on the Utility of Comparative Sequencing
    Ellie S. Hong, Wells A. Messersmith, Hazem Hammad, Toby C. Cornish, Dara L. Aisner
    JCO Precision Oncology.2022;[Epub]     CrossRef
  • Do Patients with Second Primary Colorectal Cancer Hold the Similar Prognosis and Therapeutic Benefits as Those with Initial Primary Colorectal Cancer?
    Quan Chen, Shan Zhao, Yongxi Song, Peng Gao, Jingxu Sun, Xiaowan Chen, Yu Sun, Zhenning Wang
    BioMed Research International.2018; 2018: 1.     CrossRef
  • KRASmutation status impacts diagnosis and treatment decision in a patient with two colon tumours: a case report
    Xiaodong Li, G Pezeshkpour, Ryan T Phan
    Journal of Clinical Pathology.2015; 68(1): 83.     CrossRef
  • Two Synchronous Colonic Adenocarcinomas, a Gastric Schwannoma and a Mucinous Neoplasm of the Appendix: a Case Report
    Diogo Sousa, Miguel Allen, Alda Pinto, Andreia Ferreira, Ana Cruz, Diogo Marinho, Pierpaolo Cusati, José Augusto Martins
    Journal of Gastrointestinal Cancer.2015; 46(3): 304.     CrossRef
  • KRAS and BRAF genotyping of synchronous colorectal carcinomas
    RICCARDO GIANNINI, CRISTIANA LUPI, FOTIOS LOUPAKIS, ADELE SERVADIO, CHIARA CREMOLINI, ELISA SENSI, MASSIMO CHIARUGI, CARLOTTA ANTONIOTTI, FULVIO BASOLO, ALFREDO FALCONE, GABRIELLA FONTANINI
    Oncology Letters.2014; 7(5): 1532.     CrossRef
  • Population-based data from the Swedish Colon Cancer Registry
    K Kodeda, L Nathanaelsson, B Jung, H Olsson, P Jestin, A Sjövall, B Glimelius, L Påhlman, I Syk
    British Journal of Surgery.2013; 100(8): 1100.     CrossRef
  • Metachronous carcinomas in colorectum and its clinicopathological significance
    Alfred King-Yin Lam, Vinod Gopalan, Robert Carmichael, Petra Gertraud Buettner, Melissa Leung, Robert Smith, Cu-Tai Lu, Yik-Hong Ho, Simon Siu
    International Journal of Colorectal Disease.2012; 27(10): 1303.     CrossRef
  • Metastasis at the Colostomy Site: A Rare Case Report
    Y.-H. Kuo, C.-C. Chin, K.-F. Lee
    Japanese Journal of Clinical Oncology.2012; 42(8): 753.     CrossRef
  • Total colectomy as part of primary cytoreductive surgery in advanced Müllerian cancer
    Yong Jung Song, Myong Cheol Lim, Sokbom Kang, Sang-Soo Seo, Ji Won Park, Hyo Seong Choi, Sang-Yoon Park
    Gynecologic Oncology.2009; 114(2): 183.     CrossRef
  • 9,619 View
  • 63 Download
  • 13 Crossref
Close layer
Intestinal Perforation in Colorectal Cancers Treated with Bevacizumab (Avastin®)
Young Il Choi, Seung Hyun Lee, Byung Kwon Ahn, Sung Uhn Baek, Seun Ja Park, Yang Soo Kim, Seong Hoon Shin
Cancer Res Treat. 2008;40(1):33-35.   Published online March 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.1.33
AbstractAbstract PDFPubReaderePub

Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), and it has shown promise as a clinical agent against metastatic colorectal cancer, and particularly in combination with chemotherapy. Bowel perforation is a known risk that's associated with bevacizumab use, but the etiology is unknown. Here we report on two cases of metastatic colorectal cancer in which the patients suffered from intestinal perforation after chemotherapy with bevacizumab. For the first case, a 47 year-old man had rectal cancer with concurrent liver and lung metastasis. He underwent chmotherapy with 5-fluorouracil, irinotecan and bevacizumab. Fever and abdominal pain developed seven days later, and rectal perforation was identified upon exploration 13 days later. For the second case, a 48 year-old woman had sigmoid colon cancer with peritoneal and ovary metastases. After seven days of chemotherapy with 5-fluorouracil, oxaliplatin and bevacizumab, exploratory surgery revealed a perforation at the ileum.

Citations

Citations to this article as recorded by  
  • Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)
    Jai N. Patel, Chen Jiang, Kouros Owzar, Daniel L. Hertz, Janey Wang, Flora A. Mulkey, William K. Kelly, Susan Halabi, Yoichi Furukawa, Cameron Lassiter, Susan G. Dorsey, Paula N. Friedman, Eric J. Small, Michael A. Carducci, Michael J. Kelley, Yusuke Naka
    The Pharmacogenomics Journal.2024;[Epub]     CrossRef
  • Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database
    Akihiko Ueda, Hidemichi Watari, Masaki Mandai, Shunichi Fukuhara, Yasuo Sugitani, Kiyoko Ogino, Shuichi Kamijima, Takayuki Enomoto
    Journal of Gynecologic Oncology.2022;[Epub]     CrossRef
  • Bevacizumab does not increase risk of perforation in patients undergoing percutaneous endoscopic gastrostomy or jejunostomy placement
    Pratima Dibba, Emmy Ludwig, Delia Calo, Hans Gerdes, Arnold Markowitz, Moshe Shike, Mark Schattner, Robin Mendelsohn
    Surgical Endoscopy.2021; 35(6): 2976.     CrossRef
  • Evolution of pediatric gastrointestinal ulcer disease: Is acute surgical intervention relevant?
    Alyssa D. Brown, Michael D. Traynor, D. Dean Potter, Michael B. Ishitani, Christopher R. Moir, Paul J. Galardy, Denise B. Klinkner
    Journal of Pediatric Surgery.2021; 56(10): 1870.     CrossRef
  • A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed
    Shuncong Wang, Yewei Liu, Yuanbo Feng, Jian Zhang, Johan Swinnen, Yue Li, Yicheng Ni
    Cancers.2019; 11(11): 1782.     CrossRef
  • Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer
    Motohiro Tamiya, Hidekazu Suzuki, Takayuki Shiroyama, Ayako Tanaka, Naoko Morishita, Norio Okamoto, Kenichi Sakai, Hironori Shigeoka, Kunimitsu Kawahara, Tomonori Hirashima
    Investigational New Drugs.2018; 36(4): 696.     CrossRef
  • A case of ramucirumab-related gastrointestinal perforation in gastric cancer with small bowel metastasis
    Shinya Urakawa, Daisuke Sakai, Yasuhiro Miyazaki, Toshihiro Kudo, Aya Katou, Chiaki Inagaki, Koji Tanaka, Tomoki Makino, Tsuyoshi Takahashi, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Shuji Takiguchi, Taroh Satoh, Masaki Mori, Yuichiro Doki
    Surgical Case Reports.2017;[Epub]     CrossRef
  • Sigmoid Colon Perforation Related to Bevacizumab in a Patient With Glioblastoma
    Mehmet Akif Ozturk, Baran Erdik, Orhan Onder Eren
    American Journal of Therapeutics.2016; 23(1): e241.     CrossRef
  • When a good call leads to a bad connection: colovesical fistula in colorectal cancer treated with bevacizumab
    Jeffrey Chen, Roger D. Smalligan, Suhasini Nadesan
    Hospital Practice.2016; 44(3): 120.     CrossRef
  • Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials
    Zexing Wang, Jun Zhang, Liang Zhang, Pengying Liu, Yamin Xie, Qin Zhou
    Journal of Chemotherapy.2016; 28(4): 328.     CrossRef
  • Safety and Efficacy of Palliative Colorectal Stent Placement Using a Nasal Endoscope Technique
    Taishi Hata, Shiro Hayashi, Masakazu Miyake, Shunji Morita, Keizo Dono
    Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2015; 25(3): 262.     CrossRef
  • Multidetector-row CT of tumour–bowel fistula: Experience at a tertiary cancer centre
    S.H. Tirumani, A.B. Shinagare, J.P. Jagannathan, K.M. Krajewski, N.H. Ramaiya
    Clinical Radiology.2014; 69(2): e100.     CrossRef
  • Bowel perforation associated with temsirolimus use in a recently irradiated patient
    Claire M. Mach, Anze Urh, Matthew L. Anderson
    American Journal of Health-System Pharmacy.2014; 71(11): 919.     CrossRef
  • Complications of Targeted Drug Therapies for Solid Malignancies: Manifestations and Mechanisms
    Richard G. Abramson, Vandana G. Abramson, Emily Chan, Leora Horn, Vicki L. Keedy, William Pao, Jeffrey A. Sosman
    American Journal of Roentgenology.2013; 200(3): 475.     CrossRef
  • Retinal vascular changes following intravitreal ranibizumab injections for neovascular AMD over a 1-year period
    S S Wickremasinghe, J Xie, R H Guymer, T Y Wong, R Kawasaki, S Qureshi
    Eye.2012; 26(7): 958.     CrossRef
  • Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model
    Guillaume Passot, Aurélien Dupré, Michel Rivoire, Faheez Mohamed, Naoual Bakrin, Olivier Glehen
    Clinical and Translational Oncology.2012; 14(12): 931.     CrossRef
  • Influence of Modern Systemic Therapies as Adjunct to Cytoreduction and Perioperative Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis: A Multicenter Study
    Terence C. Chua, David L. Morris, Akshat Saxena, Jesus Esquivel, Winston Liauw, Joerg Doerfer, Christoph-Thomas Germer, Alexander G. Kerscher, Joerg O. W. Pelz
    Annals of Surgical Oncology.2011; 18(6): 1560.     CrossRef
  • A Case of Severe Bevacizumab-induced Ischemic Pancolitis, Treated with Conservative Management
    Ha Ni Lee, Myung-Ah Lee, Sang Woo Kim, Yejee Lim, Hwayoung Lee, Hae Min Lee, Hye Sung Won, Sang-Hoon Chun
    The Korean Journal of Gastroenterology.2011; 58(1): 42.     CrossRef
  • Perforated Rectal Cancer Presenting as Fournier's Gangrene
    John Alfred Carr
    Journal of Clinical Oncology.2010; 28(30): e605.     CrossRef
  • 12,325 View
  • 93 Download
  • 19 Crossref
Close layer
Prognostic Factors and Survival Analysis for Patients with Colorectal Carcinomas
S H Kim, Byung Kwon Ahn, S U Baek
J Korean Cancer Assoc. 2000;32(2):331-338.
AbstractAbstract PDF
PURPOSE
Colorectal carcinomas are one of the most common malignant tumors in western countries. In Korea, it is the fourth common malignancy and the incidence has been rising over the past 10 years. We studied respectively to analyse prognostic factors in patients with colorectal cancer.
MATERIALS AND METHODS
893 patients with primary colorectal carcinomas who were operated at our hospital between 1989 and 1997 were reviewed. We examined possible prognostic factors such as, age and sex of patients, size and location of tumors, preoperative serum CEA and CA19-9 level, modified Dukes stage, operative methods, and lymph node metastases.
RESULTS
Overall 5-year survival rate was 61.8%. The 5-year survival rates in modified Dukes stage A, Bl, B2, Cl, C2 and D were 100%, 89.4%, 72.5%, 63.3%, 55.1% and 21.5%, respectively. Univariate analysis showed that age, modified Dukes stage, preoperative serum CEA and CA19-9 level, and lymphatic metastases were significant factors. The size of tumor was a significant factor in rectal carcinomas but not in colon carcinomas. In extraperitoneal rectal carcinomas, there were no survival differences between low anterior resection and abdominoperineal resection groups. Preoperative serum CEA level and modified Dukes' stage were significant in multivariate analysis, CONCLUSION: Modified Dukes stage, preoperative serum CEA were independent prognostic factors for patients with colorectal cancer.
  • 3,161 View
  • 17 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP